Is The Rally Real? Clearside Biomedical, Inc (NASDAQ:CLSD) Announces U.S. FDA Filing Acceptance

Clearside Biomedical, Inc (NASDAQ:CLSD) is the notable gainer and trading with major rally in the pre-market session  after the news this morning.

Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)

  • announced today that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™1 (triamcinolone acetonide suprachoroidal injectable suspension). FDA determined that the filing is a Class 2 resubmission and therefore assigned a Prescription Drug User Fee Act (PDUFA) action date of October 30, 2021. XIPERE is an investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.
  • XIPERE is designed for suprachoroidal administration via Clearside’s patented, proprietary SCS Microinjector® that offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The SCS Microinjector provides targeted delivery to potentially improve efficacy and compartmentalization of medication.
  •  Targeted drug delivery via the suprachoroidal space may also limit corticosteroid exposure to the anterior segment with the potential to reduce the risk of certain  adverse events, such as cataracts, intraocular pressure elevation and exacerbation of glaucoma, that can commonly arise from other local corticosteroid delivery techniques.

“The FDA’s filing acceptance for XIPERE is an exciting milestone for our collaboration with Clearside. If approved by the FDA, XIPERE would be the first therapy available utilizing the suprachoroidal space for patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis. With this acceptance, we are one step closer to providing an important novel treatment option for this patient population,” said Joseph C. Papa, chairman and CEO, Bausch Health.

Market Action

As of 8:16, CLSD stock gained $0.21 or 8% to $2.87. So far the stock has traded 22K shares traded hands.

Related Posts

About The Author